cyrilzakka/clinical-trials huggingface dataset:
Precise Antiplatelet THerapy Guided by Platelet Aggregation Function in Acute Ischemic STROKE（PATH-STROKE）

1. Main objective: To explore the efficacy of precise antiplatelet therapy guided by platelet aggregation function in reducing the incidence of 30 day platelet hyperresponsiveness in patients with non-cardiogenic ischemic stroke.
2. Secondary objective: To explore the efficacy and safety of antiplatelet therapy in patients with non-cardiogenic ischemic stroke under the guidance of platelet aggregation function.

Non cardiac cerebral infarction accounts for more than 50% of cerebral infarction cases, and the key to its onset is increased platelet aggregation function. Aspirin and clopidogrel are Class A recommended drugs for the prevention and treatment of non cardiac cerebral infarction. However, after regular use of aspirin and clopidogrel, more than 30% of stroke patients still experience high on treatment platelet reactivity (HOPR) due to aspirin resistance and clopidogrel resistance, leading to stroke recurrence. Antiplatelet therapy is the cornerstone of the prevention and treatment of non cardiogenic cerebral infarction. Therefore, clinical research on the prevention and treatment of HOPR with antiplatelet therapy for non cardiogenic cerebral infarction is of great significance, which can help partially solve the bottleneck of resistance to antiplatelet therapy in cerebral infarction.Platelet aggregation function testing can timely detect antiplatelet therapy HOPR, guide drug adjustment, and is expected to become a testing standard for the prevention and treatment of antiplatelet therapy resistance.

Eligibility Criteria:
Inclusion Criteria:

1. Aged from 18 to 80 years;
2. Diagnosed with non-cardiogenic ischemic stroke according to WHO criteria, confirmed by cranial CT or MRI to exclude hemorrhagic stroke.;
3. First stroke onset ≥ 1 month and ≤ 3 months;
4. mRS Score \<=2 points;
5. Undergoing antiplatelet therapy with 100mg aspirin daily for at least 8 days;
6. Informed consent signed by the patient or their family member.

Exclusion Criteria:

1. History of recurrent stroke.
2. History of gastrointestinal bleeding, intracranial hemorrhage, or other bleeding disorders.
3. Contraindications or intolerance to antiplatelet therapy medications.
4. Severe cardiac, pulmonary, hepatic, or renal insufficiency, or presence of severe comorbid conditions (e.g., end-stage malignant tumors, severe single/multiple organ failure).
5. Poor compliance, inability to cooperate with study requirements.
Artificial Intelligence Analysis for Magnetic Resonance Imaging in Screening Breast Cancer in High-risk Women

Use Convolutional Neural Networks Analysis for Classification of Contrast-enhancing Lesions at Multiparametric Breast MRI. Build an abbreviated protocal, and investigate whether an abbreviated protocol was suitable for breast magnetic resonance imaging screening for breast cancer in high-risk Chinese women, which can shorten the examination time and avoid enhanced imaging while ensuring the accuracy of the diagnosis.


Eligibility Criteria:
Inclusion Criteria:

* Patients undergoing full sequence BMRI examination
* Written informed consent and complete the clinical data questionnaire
* Through the follow-up database, at least 6 months of follow-up results can be obtained to determine whether the diagnosis result is negative/benign/malignant; for patients who need pathological biopsy, the pathological biopsy results shall prevail to determine the lesion benign/malignant.

Exclusion Criteria:

* The breast had received radiotherapy, chemotherapy, biology and other treatments before BMRI.
* Signs or symptoms of breast disease
* There are contraindications for breast-enhanced MRI examinations such as allergy to contrast agents.
* Patients during lactation or pregnancy
Study on the Diagnosis of Ground-glass Lung Cancer by Microwave Ablation Combined With Puncture Biopsy

This study is a multicenter study. It plans to screen 200 patients with pulmonary nodule lesions with ground glass as the main body, take CT thin-layer scanning 3D reconstruction, apply AI and fragment omics technology to evaluate the risk of malignant transformation of pulmonary nodules, and use microwave ablation to treat pulmonary nodules and combine intraoperative rapid pathology technology to determine the nature of puncture tissue and the degree of ablation, and then explore the optimal ablation time and ablation power.

Combining AI and fragmentomics technology, this study enrolled 200 patients with ground-glass lung cancer for comprehensive evaluation. By collecting detailed characteristic data of ground-glass lung cancer, including nodule diameter, average CT value, solid component ratio (CTR), nodule morphology and other related signs, CT imaging and AI technology, and fragmentomics technology were used for comprehensive analysis to form a set of joint strategies to efficiently screen and diagnose patients with early lung cancer.

Microwave ablation is used to treat lung nodules, and intraoperative rapid pathology technology is used to determine the nature of the punctured tissue and the degree of ablation (observing pathological changes in the lesion area, including cancer cell death and fibrosis of the lesion tissue), determine whether the lesion has been completely ablated, or whether there are residual active cancer cells, and then explore the optimal ablation time and ablation power.

Finally, long-term follow-up of patients after microwave ablation, including collection of intraoperative/postoperative complication data, regular CT review, evaluation of treatment effect, monitoring for recurrence, and improving individualized treatment plans for patients.

Eligibility Criteria:
Inclusion Criteria:

1. Age ≤ 75 years;
2. GGN patients with the maximum axial diameter of the lesion in the lung window ≤ 3 cm;
3. Refusing radical surgery or being unable to tolerate surgical treatment;
4. Normal coagulation function, platelet count ≥ 60 × 109 /L;
5. ECOG score ≤ 2 points;

Exclusion Criteria:

1. Patients with the maximum axial diameter of the lesion in the lung window greater than 3 cm
2. Platelets \<50×109 /L
3. Patients with severe bleeding tendency and coagulation dysfunction that cannot be corrected in the short term
4. Severe chronic obstructive pulmonary disease, emphysema, pulmonary fibrosis and pulmonary hypertension
5. Patients whose anticoagulant therapy or antiplatelet drugs have been discontinued for less than 5 days before ablation
6. Patients with severe heart, liver, kidney and brain dysfunction
7. Patients with severe anemia, dehydration and cachexia that cannot be corrected or improved in the short term
8. Patients with an estimated survival period of less than 6 months
Does the Negativation of the Glucose Hydrogen Breath Test Come Along With a Reduction of the Symptoms of Gaz Incontinence ?

The objectives of this work are: 1/to estimate the frequency of a positive glucose breath test in favour of a small intestinal bacterial overgrowth in a population of patients consulting for gaz incontinence by comparison to a population of control subjects; 2/to estimate versus a conventional treatment the efficiency of an antibiotic treatment; in case of small intestinal bacterial overgrowth diagnosed by the glucose breath test, to improve gaz incontinence


Eligibility Criteria:
Inclusion Criteria:

* Gaz incontinence for more than 3 months
* Afflilied to national health security
* Having read and sign the information letter and consent form

Exclusion Criteria:

* Pregnancy
* use of antibiotics, probiotics, IPP for less tha n 3 months
* past of small intestinal bacterial overgrowth
* ischemic, inflammatory colitis,colo-rectal cancer
* diabetes
* allergy to metronidazole
* psychiatric disease
* patients who do not speak or read french
Safety and Efficacy of STSP-0601 in Adult Patients With Hemophilia A or B Without Inhibitor

This study will assess the safety,efficacy,pharmacokinetics and pharmacodynamics of multiple-dose of STSP-0601 at two dose levels for the treatment of bleeding episodes in hemophilia A or B patients without inhibitor.


Eligibility Criteria:
Inclusion Criteria:

* 18 ≤age≤70 years of age,male;
* Hemophilia A or B patients;
* A bleeding event requiring treatment occurred (Only applicable to the on-demand treatment stage);
* Factor VIII or IX level \<2%, inhibitor titer \< 0.6 BU;
* There were at least 2 bleeding events that requiring treatment occurred in the past 6 months before screening (Only the second stage is applicable);
* Establish proper venous access;
* Agree to use adequate contraception to avoid pregnancy;
* Provide signed informed consent.

Exclusion Criteria:

* Have any coagulation disorder other than hemophilia;
* Plan to receive prophylactic treatment of coagulation factor during the trail;
* 4 weeks before screening, receive prophylactic treatment of amesetuzumab or plan to receive prophylactic treatment of amesetuzumab during the trial;
* Patients received anticoagulant or antifibrinolytic therapy 7 days before enrollment or plan to receive these drugs during the trial;
* Patients received anticoagulation therapy (such as coagulation factor replacement therapy, prothrombin complex, plasma, etc.) 7 days before enrollment;
* Have a history of arterial and/or venous thrombotic events;
* Platelet \<100×109/L;
* Hemoglobin\<90g/L;
* Severe liver or kidney disease;
* Severe bleeding event occurred within 4 weeks before enrollment;
* Accepted major operation or blood transfusion within 4 weeks before enrollment;
* HIV positive;
* Have a known allergy to STSP-0601;
* Participate in other clinical research within 4 weeks before enrollment(except for participating in prothrombin complex, FVII, FVIIa, FVIII, FIX trails);
* Patients not suitable for the trail according to the judgment of the investigators.
Corneal Versus Conjunctival Delivery Using a Delivery Device

Compare the antihypertensive efficacy of three methods for installing Xalatan


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of primary open angle glaucoma or ocular hypertension in 1 or both eyes

Exclusion Criteria:

* History of closed/barely open anterior chamber angle or a history of angle closure
The Effect of Montelukast Treatment in Wheezy Infants

The study is designed to evaluate the efficacy of montelukast on symptom-free days in unselected group of very young children with wheeze and recurrent asthma like symptoms. The secondary aim was to evaluate the effect of montelukast on lung function, airway responsiveness, airway inflammation and use of rescue medication.

The aim of this study was to investigate the effectiveness of montelukast in wheezy very young children with persistent respiratory symptoms. This study was a prospective, double-blind, placebo-controlled study of 6 to 24 months old children, who had at least one physician-diagnosed wheezing episode and persistent asthmatic symptoms. Patients were randomised to placebo or montelukast 4 mg / day for 8 weeks period. The clinical response to treatment was determined, the functional residual capacity (FRC) and specific air-way conductance (sGaw) was measured using an infant whole-body pletys-mograph, the maximal flow at functional residual capacity (V´maxFRC) was re-corded using the squeeze technique and airway responsiveness was evaluated by performing a dosimetric methacholine challenge test.

Eligibility Criteria:
Inclusion Criteria:

* at least one physician-diagnosed wheezing episode and history of recurrent cough, dyspnoea and wheeze and successfully performed methacholine challenge test were included.

Exclusion Criteria:

* use of ICS within 8 weeks prior to the first visit, a cumulative life-time systemic prednisolone use more than 3 days at a dose of 2 mg/kg, an equipotent dose of another systemic corticosteroid or ICS use more than 4 weeks, respiratory infection in the 14 days preceding lung function measurement and obvious tracheobronchomalacia or other structural defect.
Cardiovascular Disease Risk Factors in Chinese American Immigrants

The Chinese population is currently the fastest growing ethnic group in New York City (NYC). Research has shown that Chinese immigrants living in NYC have higher rates of cardiovascular disease (CVD) than individuals in China. This study will evaluate the effect that acculturation has on health habits and CVD risk factors in Chinese immigrants living in NYC.

CVD includes diseases that affect the heart and blood vessels. The underlying cause of CVD is atherosclerosis, in which fatty plaques develop on the inner walls of arteries. There are many risk factors for CVD, including inflammation, high blood pressure, high cholesterol, and obesity. Research has shown that CVD mortality rates differ greatly between Chinese immigrants living in NYC and individuals living in China. Because of this difference, it is important to understand the impact of immigration and acculturation on health habits and psychosocial factors, which may influence the development of CVD. This study will gather information from Chinese immigrants in NYC to identify the impact of immigration and acculturation on behavior and CVD risk factors. In addition, results from this study may provide insight into the CVD risk patterns in other immigrant groups.

This study will enroll Chinese immigrants living in NYC. Participants will attend one study visit and will complete questionnaires to assess their health habits (diet, physical activity, and smoking), stress levels, and socioeconomic status. Participants will also undergo a physical examination and blood collection.

Eligibility Criteria:
Inclusion Criteria:

* Chinese immigrant
* Currently residing in NYC

Exclusion Criteria:

* Under 18 years of age
* Not of Chinese dissent
* Born outside mainland China
Dispensing Evaluation of a Prototype Contact Lens and a Marketed Contact Lens

The purpose of this study is to compare visual acuity and redness of eyes between a prototype contact lens and an already marketed contact lens.


Eligibility Criteria:
Inclusion Criteria:

1. The subject must be at least 18 years of age and no more than 39 years of age.
2. The subject is a current spherical soft contact lens wearer (defined as a minimum of 6 hours of DW for a minimum of 1 month prior to the study) and willing to wear the study lenses on a daily wear basis (defined as a minimum of 6 hours of wear per day at least five days of the week) for the duration of the study.
3. The subject's optimal vertexed spherical equivalent distance correction must be between -1.00 and - 9.00D.
4. Any cylinder power must be ≤ -0.75D.
5. The subject must have visual acuity best correctable to 20/25+3 or better for each eye.
6. The subject must read and sign the Statement of Informed Consent.
7. The subject must appear able and willing to adhere to the instructions set forth in this clinical protocol.

Exclusion Criteria:

1. Ocular or systemic allergies or disease which might interfere with contact lens wear.
2. Systemic disease or use of medication which might interfere with contact lens wear.
3. Clinically significant (grade 3 or 4) corneal edema, corneal vascularization, corneal staining, or any other abnormalities of the cornea which would contraindicate contact lens wear.
4. Clinically significant (grade 3 or 4) tarsal abnormalities or bulbar injection which might interfere with contact lens wear.
5. Any ocular infection.
6. Any corneal distortion resulting from previous hard or rigid gas permeable contact lens wear.
7. Pregnancy or lactation.
8. Diabetes.
9. Infectious diseases (e.g. hepatitis, tuberculosis) or an immuno-suppressive disease (e.g. HIV).
10. Habitual contact lens type is toric, multifocal, or is worn as extended wear.
EasyCrossTM Device-Self-centering Catheter

VIVHEART EasyCross™ is a self-centering device for inserting a guidewire through a heart valve. It consists in a temporary catheter inserted into an artery with a terminal part able to expand a distal structure with 6 arms ("basket") to allow distancing of the catheter from the vessels walls and thus facilitating the passage of the guide wire through the aortic valve. The device is expected to reduce the attempts and the time needed to cross the valve and improves the safety of TAVR procedure

VIVHEART EasyCross™ is a self-centering device for inserting a guidewire through a heart valve. It consists in a temporary catheter inserted into an artery with a terminal part able to expand a distal structure with 6 arms ("basket") to allow distancing of the catheter from the vessels walls and thus facilitating the passage of the guide wire through the aortic valve. The device is expected to reduce the attempts and the time needed to cross the valve and improves the safety of TAVR procedure.

EasyCross™ device is a catheter is intended to allow a rapid and safe centering of a heart valve in order to direct and introduce a guidewire through it. The intended purpose is the use of the device during percutaneous TAVR procedures, including TAVR of a native valve, recrossing and balloon post-dilation of a prosthetic aortic valve, or a valve-in-valve aortic valve replacement within the scope of the CE mark.

The VIVHEART EasyCross™ device is intended for patients candidate to TAVR of a native valve, recrossing and balloon post-dilation of a prosthetic aortic valve, or a valve-in-valve aortic valve replacement. The suitability of the patient is to be verified case by case by the specialized physician, by means of proper physical examination and instrumental evaluation, according to clinical practice.

Eligibility Criteria:
Inclusion Criteria:

* Age: ≥18 years old
* Candidate to TAVR of a native valve, recrossing and balloon postdilation of a prosthetic aortic valve, or a valve-in-valve aortic valve replacement.
* Willingness to undergo follow-up visits.
* Ability to understand scope, content and risks of the study, and provide informed consent to participation.

Exclusion Criteria:

* Contraindications for endovascular procedures
* Pregnancy or breastfeeding females at screening and at time of investigational procedure
* Hemodynamically unstable or other clinical conditions increasing the risk of transcatheter valve procedure failure
* Needing emergent procedure
* Allergies to components of the device
* Allergies to drugs or contrast material that may be used during the investigational procedure and all the TAVR procedure
* Participation in another clinical trial
Induction of Labor - Comparison Propess with Prostaglandin E2 Vaginal Gel and Balloon Catheter

One of every four births in the Western world is induced, usually due to the risk of maternal and fetal morbidity. There are several methods of labor induction, pharmacological and mechanical. In cases of unfavorable cervix (Bishop score is below 5), cervical ripening can be induced by either prostaglandins E2 (slow release 10 mg dinoprostone insert (propess) or vaginal gel 1-2 mg) or mechanically by Foley catheter balloon (FCB).

The efficacy of labor induction of propess versus vaginal gel combined with FCB was not studied previously.

The goal of this randomized controlled trial is to compare the efficacy of propess versus PGE2 vaginal gel combined with FCB in women with singletons undergoing labor induction at term. The main question it aims to answer is to compare the time from the beginning of labor induction until delivery.


Eligibility Criteria:
Inclusion Criteria:

* Pregnant women at term (37 weeks of gestation or more) with singleton
* pregnancies that are intended for IOL.
* Initial bishop score \<5
* No contraindications to receive either treatment.
* Women who will give informed consent to be included in the study.
* Women at or over the age of 18.

Exclusion Criteria:

* Women with a known hypersensitivity or contraindications to Propess / PGE2.
* Parity 5 or more
* Labor contractions more than 4 in 20 min
* Glaucoma
* History of previous uterine surgery
* Hypersensitivity to prostaglandins
* Vaginal delivery is contraindicated
* Active cardiac, renal, pulmonary, or hepatic disease
* Severe asthma or pulmonary disease
A TMU/NIH Integrated Research Project Translation of Basic Research to Clinical Diagnosis and Treatment of Mild Traumatic Brain Injury (mTBI)

This integrated research project is cooperated by an fully-experienced team of Taipei Medical University and National Institutes of Health. We hope that we can find out the disease of balance, anxiety and sick headaches through the translation of basic research to clinical diagnosis and treatment of Mild Traumatic Brain Injury (mTBI).


Eligibility Criteria:
Inclusion Criteria:

* willing to accept this research
* age above 17 years old
* brain injury patients who are in Glasgow Coma Scale(GCS) between 13 to 15

Exclusion Criteria:

* age under 16 years old
* serious brain injury patients
* pregnant women
* people who have accepted ears surgery once
* uremia
* Liver Cirrhosis
Maxillary Sinus Augmentation Via the "Bone Lid Technique"

Maxillary sinus augmentation is one of the most performed procedures to increase the bone quantity of the atrophic maxilla in order to allow implant placement. The aim of the present case series was to describe a surgical protocol to perform maxillary sinus augmentation with the "bone lid technique", and its outcomes in a cohort of patients eligible for the procedure.


Eligibility Criteria:
Inclusion Criteria:

* Partially or fully edentulous patients requiring an implant-prosthetic rehabilitation of the premolar or molar maxillary areas with a residual ridge height lower than 4 mm.
* Patients needing for a unilateral or bilateral sinus lift with a lateral wall approach.

Exclusion Criteria:

* Patients under treatment with immunosuppressive agents
* Patients under treatment with medications that could impair bone metabolism.
* Patients pregnant or breastfeeding.
* Patients who had received irradiation treatment to the head and neck area.
* Patients with uncontrolled diabetes.
* Patients with uncontrolled periodontal disease.